Patients with psychosis and addiction: Disorder-specific treatment can help

October 30, 2015

People with psychosis often develop an addiction disorder: almost one in two patients with schizophrenia are affected once during their lifetime. Patients with a dual diagnosis mostly have a poorer prognosis, and their disorder often becomes chronic. Euphrosyne Gouzoulis-Mayfrank and colleagues investigated in a randomized controlled study in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2015; 112: 683-91) whether disorder-specific treatment can improve patients' motivation to remain abstinent and reduce their substance misuse. They applied an evaluated therapeutic program that would be easy to implement in standard care.

100 dual diagnosis patients participated in the study, who were voluntarily admitted to inpatient treatment for their disorders. While everyone received standard treatment--such as individual therapeutic sessions, therapy for their psychosis, and cognitive training--some of the patients were allocated to disorder-specific group treatments that focused on their motivation to remain abstinent as well as psychoeducation. Subsequently they were offered additional cognitive behavioural therapy on an outpatient basis. The researchers documented the course of treatment for one year and found that patients receiving disorder-specific treatment had a slightly stronger motivation for abstinence and their substance consumption was slightly lower compared with patients receiving conventional treatment. The authors stressed, however, that such treatment will yield only moderate improvements in dual diagnosis patients. Because of the limited number of study participants, they recommend verifying the results in more elaborate studies and identifying subgroups that may respond better to treatment.
-end-
http://www.aerzteblatt.de/pdf.asp?id=172416

Deutsches Aerzteblatt International

Related Psychosis Articles from Brightsurf:

Unravelling the origins of autoimmune psychosis
Anti-NMDAR encephalitis is an autoimmune brain illness that is often mistaken by a psychiatric disorder since it causes psychoses and other behaviour alterations.

Targeted treatment for depression could benefit patients with psychosis
Patients with early onset psychosis may benefit from treatment for depression, including with anti-depressants alongside other medication, new research shows.

Pimavanserin reduced symptoms of dementia-related psychosis in phase 3 trial
New data presented at the Alzheimer's Association International Conference indicates that pimavanserin leads to a robust reduction in the severity of psychosis symptoms during the 12 week open-label phase of the study, regardless of the underlying dementia subtype or the severity of participants' dementia.

Young people with early psychosis may not require antipsychotic medications to recover
Researchers at Orygen have found that some young people with early stage first episode psychosis (FEP) can experience reduced symptoms and improve functioning without antipsychotic medication when they are provided with psychological interventions and comprehensive case management.

NMDA receptors may link psychosis and sleep deficits
Sofya Kulikova, a researcher at HSE University in Perm, is part of an international research team that has discovered potential mechanisms that explain the sleep spindle deficit in electroencephalograms (EEG) of people with schizophrenia.

Almost half of all postpartum psychosis are isolated cases
A new research result from iPSYCH shows that 40% of the women who suffer a psychosis after giving birth -- known as postpartum psychosis - do not subsequently become ill again.

Thirty risk factors found during and after pregnancy for children developing psychosis
More than 30 significant risk factors have been identified for the development of psychotic disorders in offspring in research led by the NIHR Maudsley BRC.

A new window into psychosis
A recent study in mice led a team of researchers in Japan to believe that psychosis may be caused by problems with specialized nerve cells deep within the brain, as well as a certain kind of learning behavior.

New insight into how cannabidiol takes effect in the brains of people with psychosis
Researchers from King's College London have shown that cannabidiol (CBD) alters the brain activity in people with psychosis during memory tasks, making it more similar to the activation seen in people without psychosis during the same tasks.

Study finds 'cluster of disadvantage' behind BAME psychosis rates
Excess psychosis diagnoses amongst black and South Asian men in deprived urban areas could reflect a cluster of disadvantage in specific places, rather than individual experiences of deprivation alone, a study led by Queen Mary University of London researchers concludes.

Read More: Psychosis News and Psychosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.